Russia's Vector starts phase two of COVID-19 vaccine trials
The Vector State Research Center of Virology and Biotechnology in Novosibirsk has started the second phase of clinical studies of the vaccine against the novel coronavirus. All participating volunteers are in good health, Head of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Anna Popova said on Monday.
"Yes, of course [phase two has started]. Today clinical trials are held, all volunteers who were specially selected are feeling well. Those injected with the vaccine have no reactions, there are no cases of even slight reddening at the site of injection," TASS cited her as saying.
Earlier the sanitary watchdog who runs the Vector Center reported that 86 volunteers would receive the vaccine during the second phase of clinical trials.
On July 24, the Vector Center received a permit from Russia’s Healthcare Ministry to conduct clinical trials of the vaccine on volunteers. The first volunteer was inoculated on July 27. Five volunteers aged 18-30 participated in the first stage of clinical trials. Center’s General Director Rinat Maksyutov reported that the production launch of the vaccine is scheduled for November.